Rolf Hilgenfeld

机构：University of Lübeck · ORCID：0000-0001-8850-2977

发表论文 336 篇 · 总被引 19270 次 · h-index 62

代表论文

• Therapeutic strategies for COVID-19: progress and lessons learned (2023 · Nature Reviews Drug Discovery · 被引 704)
• Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase (2023 · Scientific Reports · 被引 46)
• Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease (2022 · Journal of Medicinal Chemistry · 被引 37)
• A coronavirus assembly inhibitor that targets the viral membrane protein (2025 · Nature · 被引 33)
• Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design (2024 · Nature Communications · 被引 26)
• From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease (2022 · Molecules · 被引 25)